Ocular Therapeutix (NASDAQ:OCUL) Receives “Buy” Rating from Chardan Capital

Ocular Therapeutix (NASDAQ:OCUL)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report released on Wednesday,Benzinga reports. They presently have a $21.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s price target suggests a potential upside of 200.43% from the company’s current price.

OCUL has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. HC Wainwright raised their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a report on Monday, December 8th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Finally, Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $6.99 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.85 and a beta of 0.90. The firm’s 50 day simple moving average is $11.22 and its 200-day simple moving average is $11.78. Ocular Therapeutix has a 12 month low of $5.78 and a 12 month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The business’s revenue was down 22.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.29) EPS. Analysts expect that Ocular Therapeutix will post -0.98 EPS for the current year.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Sanjay Nayak sold 10,348 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $93,545.92. Following the transaction, the insider directly owned 332,412 shares in the company, valued at approximately $3,005,004.48. The trade was a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Donald Notman sold 11,446 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $9.04, for a total transaction of $103,471.84. Following the sale, the chief operating officer directly owned 366,356 shares of the company’s stock, valued at approximately $3,311,858.24. This represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 166,029 shares of company stock valued at $1,498,430. Corporate insiders own 2.30% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after buying an additional 2,411,953 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Ocular Therapeutix by 5.1% during the 4th quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company’s stock valued at $130,842,000 after acquiring an additional 527,777 shares during the last quarter. TCG Crossover Management LLC grew its holdings in shares of Ocular Therapeutix by 15.0% in the third quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock valued at $71,510,000 after purchasing an additional 798,084 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Ocular Therapeutix by 15.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company’s stock worth $56,148,000 after purchasing an additional 620,700 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Ocular Therapeutix by 30.5% during the fourth quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company’s stock worth $52,896,000 after purchasing an additional 1,018,094 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Key Headlines Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 Phase 3 showed statistical superiority on the trial’s vision endpoint vs Regeneron’s Eylea, supporting Ocular’s plan to pursue an FDA filing — a clear clinical win that could translate into a new wet‑AMD product if regulators and payers agree. Read More.
• Positive Sentiment: Company and coverage note an FDA submission pathway and potential upside to Ocular’s product mix if AXPAXLI (SOL‑1) secures approval — this is the strategic bull case for longer‑term investors. Read More.
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the raw data are positive but market is parsing subgroup analyses, comparator details and next regulatory steps before re‑rating the stock. Read More.
• Negative Sentiment: Despite the Phase 3 win, coverage highlighted the observed clinical benefit as modest and noted that some comparisons used a lower‑dose/less favorable version of Eylea — investors questioned meaningful commercial differentiation, prompting large intraday selling. Read More.
• Negative Sentiment: Multiple insiders sold shares on Feb. 12 (notably Pravin Dugel sold 124,882 shares at ~$9.04, and several executives sold smaller blocks), which can sap market confidence even when sales may be routine or for diversification. Read More. Read More.
• Negative Sentiment: Recent quarter: EPS beat per‑share loss estimate but revenue missed and the company remains unprofitable with negative margins — factors that increase sensitivity to commercialization risk and funding needs. Read More.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.